GlobeNewswire

XBiotech Announces New Patents for Third Quarter 2018

Del

Patents Granted/Allowed for Company’s Candidate Treatments for Cardiovascular Disease, Staphylococcus Aureus Infections and its Antibody Discovery Technology

AUSTIN, Texas, Oct. 26, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it was awarded 11 new patents or patent allowances in the third quarter of 2018. Patents issued relate to the Company’s drug candidates bermekimab and 514G3, which target a crucial mediator of chronic inflammation and Staphylococcus aureus (including MRSA), respectively. The new patents include those issued from European authorities to protect bermekimab when used in the treatment of dermatological pathologies and cancer-associated cachexia.  Patent allowances include one each in Australia, Canada, Israel, Mexico, the Philippines, Russia, and South Korea that include covering: bermekimab in the treatment of cardiovascular disease; the 514G3 antibody to treat Staphylococcus aureus infections; and key aspects of the Company’s True HumanTM antibody discovery platform.

Stanley Kim, Ph.D., J.D., XBiotech’s Corporate Vice President of Intellectual Property, stated, “These recently issued patents reflect XBiotech’s efforts to develop significant worldwide protection for its emerging candidate therapies. The Company’s patent portfolio currently includes over 100 issued patents.”

XBiotech’s substantial patent portfolio supports a diverse drug development platform. The Company is currently conducting clinical research with bermekimab as a combination therapy to treat pancreatic cancer.  In addition, ongoing evaluation of results from XBiotech’s colorectal cancer programs continues to be conducted to investigate patient response to bermekimab and to further direct the Company’s oncology program. XBiotech has two separate dermatological clinical trials underway investigating response to bermekimab in patients with atopic dermatitis and hidradenitis suppurativa. Both studies are expected to be completed this year or by first quarter 2019.  The Company is also currently exploring possibilities of conducting further clinical studies with 514G3 to prevent and treat Staphylococcus aureus infections, as well as bermekimab to prevent and treat cardiovascular disease.   XBiotech continues to advance its pipeline for other infectious disease indications, including Clostridium difficile and varicella zoster virus (shingles).

About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com 
512-386-2930

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Cloudian Provides Seamless Hybrid and Multi-cloud Storage Integration for Veeam Environments22.1.2019 20:05Pressemelding

Object Storage Platform Delivers Highly Cost-effective, Exabyte-scalable Backup, Archive and Disaster Recovery Under Single Data Management Architecture SAN MATEO, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cloudian today announced that its HyperStore object storage platform integrates seamlessly with Veeam’s newest data protection software release, Veeam Availability Suite 9.5 Update 4. This integration provides new and existing Veeam customers with highly cost-effective, limitlessly scalable storage that works across public and private cloud environments. With data playing an increasingly central role in an organization’s success, keeping it safe and readily available is more critical than ever. However, doing so has become more challenging in the face of continued rapid data growth. Veeam software is designed to provide both data protection and availability for all workloads—physical, virtual and cloud—and one of the key features in the new release is support of S3-compatible object

Brookfield Asset Management Notice of 2018 Year End Results Conference Call and Webcast22.1.2019 15:37Pressemelding

Date: Thursday, February 14, 2019 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, NEWS, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE:BAM)(TSX:BAM.A)(EURONEXT AMSTERDAM:BAMA): You are invited to participate in Brookfield Asset Management’s 2018 Year End Results Conference Call & Webcast on Thursday, February 14, 2019 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on February 14th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com “News – Press Releases.” The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-866-688-9425 toll free in North America, or for overseas calls please dial 1-409-216-0815 (Conference ID: 7174879) at approximately 10:50 a.m. The Conference Call will also be Webcast live at ht

K2 Acquires Distributor K2NE, Strengthening Its Digital Process Automation Capabilities Across Europe22.1.2019 15:00Pressemelding

Acquisition expands the digital process automation company’s presence into new markets Bellevue, Wash., Jan. 22, 2019 (GLOBE NEWSWIRE) -- SourceCode Technology Holdings, Inc. (“K2”), the leader in low-code digital process automation, today announced the acquisition of one of its distributors, K2NE. With this acquisition, K2 establishes a direct presence in mainland Europe, increasing the direct customer footprint to 14 European countries, further investing and committing to growth across the continent. K2 customers will now see increased opportunities and offerings centered around strengthening their digital transformation. K2NE has a demonstrated history of strong business growth and success gaining market shares in Spain, Switzerland and Germany. “We are thrilled to welcome the K2NE team to the K2 family,” said Evan Ellis, K2 CEO. “As two organizations built around customer-first approaches to digital process automation, we can together leverage our common vision, expand our geograph

Altus Group Report Reveals Rapid Acceleration of PropTech Adoption and Rise of Disintermediation as Major Trends Impacting the Commercial Real Estate Industry in 201922.1.2019 15:00Pressemelding

Automation, use of AI and disintermediating business models having major impact on CRE industry; growing number of CRE firms are directly investing in PropTech companies TORONTO, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group”) (TSX: AIF), a leading provider of software, data solutions and independent advisory services to the global commercial real estate (“CRE”) industry, today released the latest Altus Group CRE Innovation Report. The report provides an outlook on technology trends impacting the global CRE industry and highlights the significant acceleration in adoption of property technology (“PropTech”), the effect of disintermediating technologies, as well as a growing trend of CRE firms investing directly in PropTech companies and startups themselves. According to the report, which is based on a global survey of 400 CRE executives at firms with assets under management (“AUM”) of at least US $250 million representing a total AUM of over US $2 trillion, driving

ATTO Technology is Now Certified DataCore Ready™ and will Showcase at the DataCore Partner Conference in Frankfurt, Germany22.1.2019 14:47Pressemelding

AMHERST, N.Y., Jan. 22, 2019 (GLOBE NEWSWIRE) -- ATTO Technology, Inc., a global leader of storage, network connectivity and infrastructure solutions for data-intensive computing environments for over 30 years, is proud to announce ATTO Celerity™ Gen 6 32Gb and 16Gb Fibre Channel host bus adapters (HBAs) are certified DataCore Ready™. In addition, as a member of the DataCore Ready Partner Program, ATTO will highlight its certified connectivity options for software-defined storage and data management solutions at the DataCore Partner Conference January 22-23 in Frankfurt, Germany. “We are excited to certify the ATTO Celerity HBAs as DataCore Ready as they will help IT departments achieve the flexibility and freedom that software-defined storage solutions offer, while providing the network performance and reliability that mission-critical applications need,” said Gerardo Dada, CMO of DataCore Software. “We look forward to seeing the products in action at our annual partner conference.” A

PEX Network and iGrafx Release Research Report22.1.2019 14:00Pressemelding

Primary Research and Analysis Describes Challenges and Opportunities for Digital Transformation Professionals Orlando, FL, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Today at the OPEX Week: Business Transformation World Summit, PEX Network and iGrafx announced that they completed an extensive primary research project designed to answer the question: “Disrupted or Disruptor – Which Side Are You On?” More than 150 business leaders and digital business transformation experts from 36 industries and 42 countries participated in the survey and provided detailed insights on a range of pressing topics. PEX Networks Editor, Ian Hawkins managed the project and orchestrated analysis and insights from across his organization. “I was frankly surprised and delighted with the breadth and depth of feedback we received from members of the PEX Network community,” said Hawkins. “We now have unprecedented perspective gleaned from respondents on topics like: how to select the right processes to automate, how to mea